ProCE Banner Activity

Supportive Care for Patients With Multiple Myeloma

Clinical Thought
What supportive care do you offer your patients with multiple myeloma? Read this commentary to gain expert perspectives into strategies for supportive care of patients with multiple myeloma being treated with classic and novel therapeutic agents.

Released: September 27, 2021

Expiration: September 26, 2022

Share

Faculty

Donna Catamero

Donna Catamero, ANP-BC, OCN, CCRC

Nurse Practitioner
Mount Sinai Hospital
New York, New York

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Charise Gleason

Charise Gleason, MSN, NP-C, AOCNP

VP and Chief APP Officer
Emory Healthcare
NP Myeloma Program Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Tiffany Richards

Tiffany Richards, PhD, ANP-BC, AOCNP

Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Oncopeptides

Sanofi Genzyme Corp

Faculty Disclosure

Primary Author

Donna Catamero, ANP-BC, OCN, CCRC

Nurse Practitioner
Mount Sinai Hospital
New York, New York

Donna Catamero, ANP-BC, OCN, CCRC, has disclosed that she has received fees for non-CME/CE services from GlaxoSmithKline and Oncopeptides and has received consulting fees, has ownership interest in, and has previously received salary from Celgene/Bristol-Myers Squibb.

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Beth Faiman, PhD, MSN, APRN-BC, AOCN, has disclosed that she has received consulting fees from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, and Sanofi.

Charise Gleason, MSN, NP-C, AOCNP

VP and Chief APP Officer
Emory Healthcare
NP Myeloma Program Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Charise Gleason, MSN, NP-BC, AOCNP, has no relevant conflicts of interest to report.

Tiffany Richards, PhD, ANP-BC, AOCNP

Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Tiffany Richards, PhD, ANP-BC, AOCNP, has disclosed that she has received consulting fees from Celgene, GlaxoSmithKline, and Takeda.